



# Carbonic anhydrases: One target for multiple diseases

RNDr. Eva Havránková, PhD.

1 Department of the Chemical Drugs, Masaryk University Brno





Biochem. J. (2016) **473**, 2023–2032

3

## **CA families**

α-CAs	vertebrates, protozoa, algae, cytoplasm of green plants, Gram <sup>-</sup> bacteria
β-CAs	Gram <sup>-</sup> bacteria, Gram <sup>+</sup> bacteria, algae, chloroplasts of mono- and di- cotyledons, fungi, <i>Archaea</i>
γ-CAs	Archaea, cyanobacteria and most types of bacteria
δ-CAs	marine diatoms
ζ-CAs	marine diatoms
η-CAs	protozoa
θ-Cas	marine diatoms
ı-CAs	marine diatoms
Mod Ros Roy 2020:40:1	2485-2565; <b>Biochem J. (2016) 473</b> 2023-2032

PHARM

<sup>4</sup> Med Res Rev. 2020;40:2485–2565; Biochem. J. (2016) **473**, 2023–2032

# **CA presence in the cells**

Membrane-	Trans-	Mitochondria	Saliva and
	membrane	CA VA	milk
• CA IV	CAIX	CAVB	• CA VI
	CA XII		
	CA XIV		
	Membrane- bound • CAIV	boundmembrane• CA IV• CA IX• CA XII	boundmembrane• CA VA• CA IV• CA IX• CA VB• CA XII• CA VII

## CA presence in organs/tissue

CA Erythroo gastrointes (GIT), ar	cytes, tinal tract	Erythroc GIT, bone kidney, lu	<b>A II</b> ytes, eye, osteoclasts, ing, testis, brain	CA III Kidne Skeletal muscle and pancre adipocytes capillari		<b>A IV</b> y, lung, as, brain es, colon, cle, and eye	Liver, H skeleta pancrea	<b>A V</b> Heart and Il muscle, as, kidney, rd, and GIT	
CA Salivar mammar	y and	Central	VII nervous n (CNS)	Central	VIII nervous (CNS)	<b>CA IX</b> Tumors and gastrointestinal mucosa		Centra	<b>A X</b> I nervous m (CNS)
	system (CNS) reproductiv		<b>XII</b> intestine, re epithelia, s, and CNS	Kidney, I gut, and r	XIII orain, lung, reproductive ract	CA Kidney, bi and	rain, liver,		

MUNI

PHARM

6 Med Res Rev. 2020;40:2485–2565

# hCAs are involved in...

- Respiration
- Transportation of CO<sub>2</sub> and bicarbonate
- pH and CO<sub>2</sub> homeostasis
- Electrolyte secretion in various tissues
- Biosynthetic reactions
- Gluconeogenesis
- Adipogenesis
- Ureagenesis
- Bone resorption
- Calcification

$O=C=O + H_2O \iff HCO_3^- + H^+$ 1	
$O=C=NH + H_2O \iff H_2NCOOH 2$	
$HN=C=NH + H_2O \iff NH_2CONH_2$ 3	
R-CHO + $H_2O \iff RCH(OH)_2$ 4	
$RCOOAr + H_2O \iff RCOOH + ArOH 5$	
$RSO_3Ar + H_2O \iff RSO_3H + ArOH$	6
$NO_2$ $O_2N - F + H_2O \longrightarrow O_2N - OH$	7
PhCH <sub>2</sub> OCOCI + H <sub>2</sub> O $\checkmark$ PhCH <sub>2</sub> OH + CO <sub>2</sub> + HCI	
$RSO_2CI + H_2O \iff RSO_3H + HCI [R=Me, Ph]$	

R


8

9

# In which form is most of the carbon dioxide transported through the bloodstream?

- dissolved in plasma
- Bonded to haemaglobine in form of carbaminohaemaglobine
- Converted into hydrogencarbonate ions and then transported in plasma

# CA in the breathing cycle




MUNI Pharm

#### **CA Mechanism of Action**

$$\mathrm{EZn}^{2+}-\mathrm{OH}^{-}+\mathrm{CO}_{2} \Longleftrightarrow \mathrm{EZn}^{2+}-\mathrm{HCO}_{3}^{-}$$

 $EZn^{2+}-HCO_3^- \iff EZn^{2+}-OH_2 + HCO_3^-$ 

$$EZn^{2+}-OH_2 \iff EZn^{2+}-HO^-+H^+$$



MUNI Pharm

# How CA can be used in therapy?




# Inhibitors of CAs

# Activators of CAs

Deficit of CAs

### **Overexpression/deficit of CAs**



#### 13 Med Res Rev. 2020;40:2485-2565


# How many mechanism of inhibition


# of carbonic anhydrases do we

# know?


#### **CA Inhibitors Mechanism of Action**

#### **The Zinc Binders**





acetazolamide




SLC-0111

PHARM


15 J. Enzyme Inhib. Med. Chem.2016;31: 345-360

#### **CA Inhibitors Mechanism of Action**




# CAIs anchoring to the zinc-coordinated water/hydroxide ion


16




#### **CA Inhibitors Mechanism of Action**

CA inhibition by occlusion of the active site entrance










PHA

RM



17 J. Enzyme Inhib. Med. Chem.2016;31: 345-360







18 J. Enzyme Inhib. Med. Chem.2016;31: 345-360

#### **CA Mechanism of Action**

Compounds acting as CAIs with an unknown mechanism of action



19 J. Enzyme Inhib. Med. Chem.2016;31: 345-360



20 Med Res Rev. 2020;40:2485–2565


MUNI Pharm

# How to discover new selective inhibitors ?

MUNI Pharm

Knowledge of the structre Screening of anions How to discover new Screening of selective drugs inhibitors? Combination of approaches Steal other people's work

## **Knowledge of the structure**




- X-ray crystal structure of CA IX
- NMR
- other

<sup>23</sup> FEBS Lett. 2004;577:439–445; Metabolites. 2017;7:48


# **Screening of anions**


	K <sub>I</sub> [mM]					
	hCA I <sup>a</sup>	hCA II <sup>a</sup>	hCA III <sup>a</sup>	hCA VII <sup>f</sup>	hCA IX <sup>g</sup>	hCA XII <sup>h</sup>
$F^{-}$	>300	>300	78.5	1.24	48	0.56
$Cl^{-}$	6	200	0.98	1.84	33	73
Br <sup></sup>	4	63	0.96	1.06	16	82
Ι-	0.3	26	0.90	0.25	7	215
$CN^{-}$	0.0005	0.02	0.06	9.2	0.004	0.001
$CNO^{-}$	0.0007	0.03	0.57	15.2	0.043	0.73
$SCN^{-}$	0.1	1.6	0.09	0.17	0.13	0.80
$N_3^-$	0.0012	1.5	0.087	1.41	0.005	0.08
$HCO_3^-$	12	85	0.74	0.16	13	0.75
$CO_{3}^{2}$	15	73	0.01	0.27	29	0.64
$HSO_3^-$	18	89	1.06	7.3	75	0.84
$NO_3^-$	7	35	117	0.19	46	79
$NO_2^-$	8.4	63	53	1.78	42	94
HS <sup></sup>	0.0006	0.04	0.08	1.24	0.007	4.8
$SO_4^2$	63	>200	1.00	1.38	>200	0.77
$H_2NSO_3^-$	0.021	0.39	31.1	0.0095	0.09	0.70
H <sub>2</sub> NSO <sub>2</sub> NH <sup>-</sup>	0.31	1.13	1.09	0.0068	0.096	0.83




# **Screening of known drugs**

\_0







MTZ



AAZ



DZA



SO<sub>2</sub>NH<sub>2</sub> BRZ

Compound	K <sub>l</sub> * (nM)				
	hCA I	hCA II	hCA IX		
AAZ	250	12.1	25.8		
BRZ	NT	3	37		
DCP	1200	38	50		
DZA	50 000	9	52		
EZA	25	8	34		
IND	31	15	24		
MZA	50	14	27		


PHARM

25 J. Med. Chem. 2020; (63)13: 7422-7444

# How to treat cancer – Inhibition of hCA IX ?



## Which isoenzyme is involved in the cancer?



# Hypoxia $\rightarrow$ HIF-1 $\rightarrow$ aggressive tumor

Metabolites. 2017;7:48; Cancer Metastasis Rev. 2019;38:65–77; Natl. Cancer Inst. 2001;93;266–276.;
Cancer Cell. 2008;13:472–482; Nat. Rev. Drug Discov. 2008;7:168–181; Nat. Rev. Drug Discov. 2011;10:767–777.

# hCA IX – How it helps the tumor

Catalytic hydration of CO<sub>2</sub>

Maintaining pHe and pHi

# Up-regulation of metabolism

Increased adhesion ability


Migration Invasion Metastasis

Interaction with signal cascades

Support of angiogenesis


MUNI Pharm

# What the hCA IX inhibitors do?



- No cytotoxicity (cytostatic effect)
- Inhibit all of the previously mentioned processes
- Prevents the formation and
- spread of metastasis
- Multiply increases sensitivity
- to existing treatments






Eur. J. Med. Chem. 2022;228:114008; Eur. J. Med. Chem. 2021;216:113283

31

# What about bacterial CAs ?

# **Bacterial CA**




#### Inhibition of CA:

- disruption of essentials metabolic pathways
- growth retardation
- growth defects
- volnurable to host
- defense mechanism

PHARM

## **Bacterial CA**



# **Does it have potential?**

- Wide range of disseases
- Effective treatment
- Great potential
- But.....



# Thank you for your attention.